2022 Publications
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.Cancer Cell. 2022 Apr 6:S1535-6108(22)00147-7. doi: 10.1016/j.ccell.2022.03.013. Online ahead of print.PMID: 35390296
Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.EBioMedicine. 2022 Mar 30;78:103972. doi: 10.1016/j.ebiom.2022.103972. Online ahead of print.PMID: 35366624
Detection of Velogenic Avian Paramyxoviruses in Rock Doves in New York City, New York.Microbiol Spectr. 2022 Mar 31:e0206121. doi: 10.1128/spectrum.02061-21. Online ahead of print.PMID: 35357204
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.Sci Transl Med. 2022 Mar 29:eabm2311. doi: 10.1126/scitranslmed.abm2311. Online ahead of print.PMID: 35348368
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.EClinicalMedicine. 2022 Mar 8;45:101323. doi: 10.1016/j.eclinm.2022.101323. eCollection 2022 Mar.PMID: 35284808
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.medRxiv. 2022 Mar 14:2022.02.27.22271399. doi: 10.1101/2022.02.27.22271399. Preprint.PMID: 35262095
Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. Front Immunol. 2022 Feb 7;13:796481. doi: 10.3389/fimmu.2022.796481. eCollection 2022.PMID: 35197972
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.medRxiv. 2022 Feb 9:2022.02.08.22270676. doi: 10.1101/2022.02.08.22270676. Preprint.PMID: 35169806
Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models.Toxicol Pathol. 2022 Feb 5:1926233211072767. doi: 10.1177/01926233211072767. Online ahead of print.PMID: 35128980
Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot.Nat Commun. 2022 Feb 1;13(1):612. doi: 10.1038/s41467-022-28233-8.PMID: 35105889
mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.Immunity. 2022 Feb 8;55(2):355-365.e4. doi: 10.1016/j.immuni.2022.01.001. Epub 2022 Jan 6.PMID: 35090580
Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature. 2022 Feb;602(7896):314-320. doi: 10.1038/s41586-021-04356-8. Epub 2021 Dec 23.PMID: 34942633
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022 Jan;22(1):57-65. doi: 10.1038/s41577-021-00662-4. Epub 2021 Dec 7.PMID: 34876702
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.Sci Transl Med. 2022 Feb 2;14(630):eabm3302. doi: 10.1126/scitranslmed.abm3302. Epub 2022 Feb 2.PMID: 34846168
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.J Thorac Oncol. 2022 Feb;17(2):214-227. doi: 10.1016/j.jtho.2021.11.001. Epub 2021 Nov 10.PMID: 34774792
Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model.J Virol. 2022 Jan 26;96(2):e0142121. doi: 10.1128/JVI.01421-21. Epub 2021 Oct 20.PMID: 34669506
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.Mol Ther. 2022 Jan 6:S1525-0016(22)00011-9. doi: 10.1016/j.ymthe.2022.01.011. Online ahead of print.PMID: 34999208
2021 Publications
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.Nature. 2021 Dec 31. doi: 10.1038/s41586-022-04399-5. Online ahead of print.PMID: 35016197
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virusPLoS Biol. 2021 Dec 16;19(12):e3001384. doi: 10.1371/journal.pbio.3001384. eCollection 2021 Dec.PMID: 34914685
Host predictors of broadly cross-reactive antibodies against SARS-CoV-2 variants of concern differ between infection and vaccination. Clin Infect Dis. 2021 Dec 10:ciab996. doi: 10.1093/cid/ciab996. Online ahead of print.PMID: 34891165
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci Immunol. 2021 Dec 10;6(66):eabj5129. doi: 10.1126/sciimmunol.abj5129. Epub 2021 Dec 10.PMID: 34890255
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.Nat Rev Immunol. 2021 Dec 7:1-9. doi: 10.1038/s41577-021-00662-4. Online ahead of print.PMID: 34876702
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.Front Immunol. 2021 Nov 18;12:791764. doi: 10.3389/fimmu.2021.791764. eCollection 2021.PMID: 34868082
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021 Nov 4;54(12):2877-2892.e7. doi: 10.1016/j.immuni.2021.11.001. Online ahead of print.PMID: 34852217
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.
Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. Heliyon. 2021 Dec;7(12):e08444. doi: 10.1016/j.heliyon.2021.e08444. Epub 2021 Nov 20.PMID: 34841098
Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-α inhibitors. Med (N Y). 2021 Nov 18. doi: 10.1016/j.medj.2021.11.004. Online ahead of print.PMID: 34812429
A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. mBio. 2021 Nov 23:e0224121. doi: 10.1128/mBio.02241-21. Online ahead of print.PMID: 34809451
SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort. Paediatr Perinat Epidemiol. 2021 Nov 21. doi: 10.1111/ppe.12812. Online ahead of print.PMID: 34806193
Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. iScience. 2021 Oct 21;24(11):103328. doi: 10.1016/j.isci.2021.103328. eCollection 2021 Nov 19.PMID: 34805790
Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination. Nat Commun. 2021 Nov 18;12(1):6720. doi: 10.1038/s41467-021-27064-3.PMID: 34795301
Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. mBio. 2021 Nov 16:e0297521. doi: 10.1128/mBio.02975-21. Online ahead of print.PMID: 34781736
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus.
Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice . Front Immunol. 2021 Sep 16;12:746447. doi: 10.3389/fimmu.2021.746447. eCollection 2021.PMID: 34603333
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial. medRxiv. 2021 Sep 22:2021.09.17.21263758. doi: 10.1101/2021.09.17.21263758. Preprint.PMID: 34580673
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. mBio. 2021 Sep 21:e0190821. doi: 10.1128/mBio.01908-21. Online ahead of print.PMID: 34544278
Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles. bioRxiv. 2021 Aug 31:2021.08.31.458247. doi: 10.1101/2021.08.31.458247. Preprint.PMID: 34494026
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination. Cell Rep Med. 2021 Aug 31:100405. doi: 10.1016/j.xcrm.2021.100405. Online ahead of print.PMID: 34485950
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol Ther Methods Clin Dev. 2021 Jun 12;22:84-95. doi: 10.1016/j.omtm.2021.06.003. eCollection 2021 Sep 10.PMID: 34485597
Influenza A viruses balance ER stress with host protein synthesis shutoff. Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):e2024681118. doi: 10.1073/pnas.2024681118.PMID: 34479996
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity. 2021 Aug 17;54(9):2159-2166.e6. doi: 10.1016/j.immuni.2021.08.013. Online ahead of print.PMID: 34464596
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. bioRxiv. 2021 Aug 26:2021.08.25.457693. doi: 10.1101/2021.08.25.457693. Preprint.PMID: 34462745
Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity. Res Sq. 2021 Aug 26:rs.3.rs-802084. doi: 10.21203/rs.3.rs-802084/v1. Preprint.PMID: 34462740
The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination. Vaccines (Basel). 2021 Aug 2;9(8):846. doi: 10.3390/vaccines9080846.PMID: 34451971
Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control. Am J Infect Control. 2021 Aug 20:S0196-6553(21)00549-6. doi: 10.1016/j.ajic.2021.08.015. Online ahead of print.PMID: 34425179
FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection. J Immunol. 2021 Sep 1;207(5):1310-1321. doi: 10.4049/jimmunol.2100297. Epub 2021 Aug 11.PMID: 34380652
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study.Sci Immunol. 2021 Aug 10;6(62):eabf3733. doi: 10.1126/sciimmunol.abf3733.PMID: 34376480
Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. Viruses. 2021 Jul 15;13(7):1371. doi: 10.3390/v13071371.PMID: 34372581
Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. iScience. 2021 Sep 24;24(9):102937. doi: 10.1016/j.isci.2021.102937. Epub 2021 Jul 31.PMID: 34368647
Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection. Vaccine. 2021 Aug 23;39(36):5205-5213. doi: 10.1016/j.vaccine.2021.06.085. Epub 2021 Aug 3.PMID: 34362603
Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components. Front Immunol. 2021 Jul 14;12:692151. doi: 10.3389/fimmu.2021.692151. eCollection 2021.PMID: 34335601
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med. 2021 Jul 27:eabh0755. doi: 10.1126/scitranslmed.abh0755. Online ahead of print.PMID: 34315826
Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike.Res Sq. 2021 Jul 19:rs.3.rs-678247. doi: 10.21203/rs.3.rs-678247/v1. Preprint.PMID: 34312615
Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner. mBio. 2021 Jul 27:e0100221. doi: 10.1128/mBio.01002-21. Online ahead of print.PMID: 34311574
Corrigendum: Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine. Angew Chem Int Ed Engl. 2021 Jul 26;60(31):16741-16742. doi: 10.1002/anie.202105635.PMID: 34278670
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial.NPJ Vaccines. 2021 Jul 14;6(1):89. doi: 10.1038/s41541-021-00353-0.PMID: 34262052
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021 Jun 29:S1535-6108(21)00336-6. doi: 10.1016/j.ccell.2021.06.014. Online ahead of print.PMID: 34242572
A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021 Jul 8. doi: 10.1038/s41591-021-01432-4. Online ahead of print.PMID: 34239135
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021 Jun 8:S0092-8674(21)00706-6. doi: 10.1016/j.cell.2021.06.005. Online ahead of print.PMID: 34192529
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.Nature. 2021 Jun 28. doi: 10.1038/s41586-021-03738-2. Online ahead of print.PMID: 34182569
Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19.Sci Rep. 2021 Jun 25;11(1):13308. doi: 10.1038/s41598-021-92740-9.PMID: 34172783
Immunological imprinting of the antibody response in COVID-19 patients.Nat Commun. 2021 Jun 18;12(1):3781. doi: 10.1038/s41467-021-23977-1.PMID: 34145263
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 Jun 9. doi: 10.1038/s41586-021-03681-2. Online ahead of print.PMID: 3410752
Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave. Nat Commun. 2021 Jun 8;12(1):3463. doi: 10.1038/s41467-021-23688-7.PMID: 34103497
First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Sci Transl Med. 2021 Jun 2;13(596):eabg4535. doi: 10.1126/scitranslmed.abg4535.PMID: 34078743
SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine. 2021 May 25;68:103401. doi: 10.1016/j.ebiom.2021.103401. Online ahead of print.PMID: 34051441
Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines.medRxiv. 2021 May 18:2021.05.17.21257197. doi: 10.1101/2021.05.17.21257197. Preprint.PMID: 34031662
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets.Immunity. 2021 May 6:S1074-7613(21)00198-9. doi: 10.1016/j.immuni.2021.05.001. Online ahead of print.PMID: 34022127
CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity.Immunity. 2021 May 11;54(5):1066-1082.e5. doi: 10.1016/j.immuni.2021.04.009. Epub 2021 Apr 15.PMID: 33951417
Refocusing the Immune Response to Selected Epitopes on a Zika Virus Protein Antigen by Nanopatterning.Adv Healthc Mater. 2021 Apr 30:e2002140. doi: 10.1002/adhm.202002140. Online ahead of print.PMID: 33929789
Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice.Vaccines (Basel). 2021 Apr 19;9(4):404. doi: 10.3390/vaccines9040404.PMID: 33921722
Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study.Lancet Reg Health Eur. 2021 Apr;3:100014. doi: 10.1016/j.lanepe.2020.100014. Epub 2021 Mar 31.PMID: 33871470
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.Lancet Respir Med. 2021 Apr 15:S2213-2600(21)00158-2. doi: 10.1016/S2213-2600(21)00158-2. Online ahead of print.PMID: 33865504
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.Lancet Microbe. 2021 Apr 7. doi: 10.1016/S2666-5247(21)00068-9. Online ahead of print.PMID: 33846703
Correlates of protection from SARS-CoV-2 infection.Lancet. 2021 Apr 17;397(10283):1421-1423. doi: 10.1016/S0140-6736(21)00782-0. Epub 2021 Apr 9.PMID: 33844964
Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers.J Infect Dis. 2021 Apr 2:jiab176. doi: 10.1093/infdis/jiab176. Online ahead of print.PMID: 33822097
Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response.NPJ Vaccines. 2021 Apr 1;6(1):45. doi: 10.1038/s41541-021-00308-5.PMID: 33795694
Systems serology detects functionally distinct coronavirus antibody features in children and elderly.Nat Commun. 2021 Apr 1;12(1):2037. doi: 10.1038/s41467-021-22236-7.PMID: 33795692
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.bioRxiv. 2021 Mar 24:2021.03.24.436864. doi: 10.1101/2021.03.24.436864. Preprint.PMID: 33791696
Inhibition of HECT E3 ligases as potential therapy for COVID-19.Cell Death Dis. 2021 Mar 24;12(4):310. doi: 10.1038/s41419-021-03513-1.PMID: 33762578
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD.medRxiv. 2021 Mar 9:2021.03.07.21253098. doi: 10.1101/2021.03.07.21253098. Preprint.PMID: 33758878
AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets.NPJ Vaccines. 2021 Mar 19;6(1):40. doi: 10.1038/s41541-021-00299-3.PMID: 33742000
Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.Cell Rep Med. 2021 Mar 16;2(3):100208. doi: 10.1016/j.xcrm.2021.100208. Epub 2021 Feb 5.PMID: 33564749
The first 12 months of COVID-19: a timeline of immunological insights.Nat Rev Immunol. 2021 Apr;21(4):245-256. doi: 10.1038/s41577-021-00522-1. Epub 2021 Mar 15.PMID: 33723416
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.PMID: 33691060
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.medRxiv. 2021 Jan 29:2021.01.26.21250543. doi: 10.1101/2021.01.26.21250543. Preprint.PMID: 33532796
Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features.Clin Transl Immunology. 2021 Feb 28;10(3):e1258. doi: 10.1002/cti2.1258. eCollection 2021.PMID: 33680466
SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital – New York City, April 2020.MMWR Morb Mortal Wkly Rep. 2021 Mar 5;70(9):308-311. doi: 10.15585/mmwr.mm7009a3.PMID: 33661864
Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.mBio. 2021 Mar 2;12(2):e02648-20. doi: 10.1128/mBio.02648-20.PMID: 33653892
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.Res Sq. 2021 Feb 15:rs.3.rs-200342. doi: 10.21203/rs.3.rs-200342/v1. Preprint.PMID: 33619473
Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.bioRxiv. 2020 Dec 18:2020.11.15.383323. doi: 10.1101/2020.11.15.383323. Preprint.PMID: 33442687
Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.mBio. 2021 Feb 16;12(1):e02492-20. doi: 10.1128/mBio.02492-20.PMID: 33593976
Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.mBio. 2021 Feb 16;12(1):e03617-20. doi: 10.1128/mBio.03617-20.PMID: 33593972
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes.Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):e2018102118. doi: 10.1073/pnas.2018102118.PMID: 33593910
Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase.mSphere. 2021 Feb 10;6(1):e00958-20. doi: 10.1128/mSphere.00958-20.PMID: 33568453
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.bioRxiv. 2021 Feb 5:2021.02.05.429759. doi: 10.1101/2021.02.05.429759. Preprint.PMID: 33564763
The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera.medRxiv. 2021 Jan 20:2021.01.19.21249592. doi: 10.1101/2021.01.19.21249592. Preprint.PMID: 33501468
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. J Clin Invest. 2021 Mar 1;131(5):e140794. doi: 10.1172/JCI140794.PMID: 33529172
Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time? Med (N Y). 2020 Dec 18;1(1):28-32. doi: 10.1016/j.medj.2020.11.004. Epub 2020 Dec 5.PMID: 33521752
Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit.Kidney Int. 2021 Feb;99(2):484-486. doi: 10.1016/j.kint.2020.11.014.PMID: 33509357
A 10-Minute “Mix and Read” Antibody Assay for SARS-CoV-2.Viruses. 2021 Jan 20;13(2):143. doi: 10.3390/v13020143.PMID: 33498157
Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers.medRxiv. 2021 Jan 15:2021.01.12.21249683. doi: 10.1101/2021.01.12.21249683. Preprint.PMID: 33469594
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20.PMID: 33472895
SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.mBio. 2021 Jan 19;12(1):e02940-20. doi: 10.1128/mBio.02940-20.PMID: 33468695
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.Angew Chem Int Ed Engl. 2021 Apr 19;60(17):9467-9473. doi: 10.1002/anie.202015362. Epub 2021 Mar 11.PMID: 33464672
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques.bioRxiv. 2021 Jan 11:2021.01.09.426058. doi: 10.1101/2021.01.09.426058. Preprint.PMID: 33447831
Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model.Vaccines (Basel). 2021 Jan 11;9(1):40. doi: 10.3390/vaccines9010040.PMID: 33440898
Heterologous viral protein interactions within licensed seasonal influenza virus vaccines.NPJ Vaccines. 2020 Jan 10;5(1):3. doi: 10.1038/s41541-019-0153-1.PMID: 33420089
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.Science. 2021 Feb 5;371(6529):eabf4063. doi: 10.1126/science.abf4063. Epub 2021 Jan 6.PMID: 33408181
2020 Publications
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.Vaccines (Basel). 2020 Dec 17;8(4):771. doi: 10.3390/vaccines8040771.PMID: 33348607
H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.mBio. 2020 Dec 15;11(6):e02090-20. doi: 10.1128/mBio.02090-20.PMID: 33323511
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.Sci Transl Med. 2020 Dec 9;12(573):eabd3601. doi: 10.1126/scitranslmed.abd3601.PMID: 33298562
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.Immunity. 2020 Dec 15;53(6):1281-1295.e5. doi: 10.1016/j.immuni.2020.11.009. Epub 2020 Nov 21.PMID: 33296685
Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients.Cell Rep Med. 2020 Nov 3;1(8):100130. doi: 10.1016/j.xcrm.2020.100130. eCollection 2020 Nov 17.PMID: 33294855
Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice.Vaccine. 2020 Dec 5:S0264-410X(20)31510-3. doi: 10.1016/j.vaccine.2020.11.057. Online ahead of print.PMID: 33293159
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7.PMID: 33288923
Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology.Clin Infect Dis. 2020 Nov 30:ciaa1781. doi: 10.1093/cid/ciaa1781. Online ahead of print.PMID: 33252647
SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.J Infect Dis. 2021 Feb 24;223(4):589-599. doi: 10.1093/infdis/jiaa737.PMID: 33247924
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.EBioMedicine. 2020 Dec;62:103132. doi: 10.1016/j.ebiom.2020.103132. Epub 2020 Nov 21.PMID: 33232870
Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients.Front Pediatr. 2020 Oct 30;8:601327. doi: 10.3389/fped.2020.601327. eCollection 2020.PMID: 33194930
Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.Vaccines (Basel). 2020 Nov 9;8(4):666. doi: 10.3390/vaccines8040666.PMID: 33182279
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City.Nature. 2021 Feb;590(7844):146-150. doi: 10.1038/s41586-020-2912-6. Epub 2020 Nov 3.PMID: 33142304
Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk.iScience. 2020 Nov 20;23(11):101735. doi: 10.1016/j.isci.2020.101735. Epub 2020 Oct 26.PMID: 33134887
Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2 Transfusion. 2021 Jan;61(1):78-93. doi: 10.1111/trf.16177. Epub 2020 Nov 20.PMID: 33125158
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.PMID: 33115920
bioRxiv. 2020 Oct 23:2020.10.23.344085. doi: 10.1101/2020.10.23.344085. Preprint.PMID: 33106810
Neutralizing Antibody Responses in COVID-19 Convalescent Sera. Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, Arinsburg S, Nguyen FT, Mendu DR, Firpo-Betancourt A, Jhang J, Wajnberg A, Krammer F, Cordon-Cardo C, Amler S, Montecalvo M, Hutton B, Taylor J, McDonough KA.
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Guthmiller JJ, Lan LY, Fernández-Quintero ML, Han J, Utset HA, Bitar DJ, Hamel NJ, Stovicek O, Li L, Tepora M, Henry C, Neu KE, Dugan HL, Borowska MT, Chen YQ, Liu STH, Stamper CT, Zheng NY, Huang M, Palm AE, García-Sastre A, Nachbagauer R, Palese P, Coughlan L, Krammer F, Ward AB, Liedl KR, Wilson PC.
In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant. Gupta A, Malhotra Y, Patil U, Muradas AR, Lee WT, Krammer F, Amanat F, Clare CA, Vinod S, Ghaly E.
COVID-19: Staging of a New Disease. Cordon-Cardo C, Pujadas E, Wajnberg A, Sebra R, Patel G, Firpo-Betancourt A, Fowkes M, Sordillo E, Paniz-Mondolfi A, Gregory J, Krammer F, Simon V, Isola L, Soon-Shiong P, Aberg JA, Fuster V, Reich DL.
Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini MB.
Scientific consensus on the COVID-19 pandemic: we need to act now. Alwan NA, Burgess RA, Ashworth S, Beale R, Bhadelia N, Bogaert D, Dowd J, Eckerle I, Goldman LR, Greenhalgh T, Gurdasani D, Hamdy A, Hanage WP, Hodcroft EB, Hyde Z, Kellam P, Kelly-Irving M, Krammer F, Lipsitch M, McNally A, McKee M, Nouri A, Pimenta D, Priesemann V, Rutter H, Silver J, Sridhar D, Swanton C, Walensky RP, Yamey G, Ziauddeen H.
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, Mendu R, Jhang J, Arinsburg S, Gitman M, Houldsworth J, Sordillo E, Paniz-Mondolfi A, Baine I, Simon V, Aberg J, Krammer F, Reich D, Cordon-Cardo C.
Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model. Amanat F, Strohmeier S, Rathnasinghe R, Schotsaert M, Coughlan L, García-Sastre A, Krammer F. 2020 Sep 17. PMID: 32995785
Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. Wilson P, Stamper C, Dugan H, Li L, Asby N, Halfmann P, Guthmiller J, Zheng NY, Huang M, Stovicek O, Wang J, Madariaga ML, Shanmugarajah K, Jansen M, Amanat F, Stewart I, Changrob S, Utset H, Huang J, Nelson C, Dai YN, Hall P, Jedrzejczak R, Joachimiak A, Krammer F, Fremont D, Kawaoka Y. 2020 Sep 25. PMID: 32995763
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, O’Donnell T, Merritt E, Simons NW, Barcessat V, Del Valle DM, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Laserson U, Rahman A, Kim-Schulze S, Charney AW, Gnjatic S, Gelb BD, Merad M, Bogunovic D. 2020 Sep 14. PMID: 32991843
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. Madsen A, Dai YN, McMahon M, Schmitz AJ, Turner JS, Tan J, Lei T, Alsoussi WB, Strohmeier S, Amor M, Mohammed BM, Mudd PA, Simon V, Cox RJ, Fremont DH, Krammer F, Ellebedy AH. 2020 Sep 22. PMID: 32976769
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodi F, Korniotis S, Karpf L, Philippot Q, Chbihi M, Bonnet-Madin L, Dorgham K, Smith N, Schneider WM, Razooky BS, Hoffmann HH, Michailidis E, Moens L, Han JE, Lorenzo L, Bizien L, Meade P, Neehus AL, Ugurbil AC, Corneau A, Kerner G, Zhang P, Rapaport F, Seeleuthner Y, Manry J, Masson C, Schmitt Y, Schlüter A, Le Voyer T, Khan T, Li J, Fellay J, Roussel L, Shahrooei M, Alosaimi MF, Mansouri D, Al-Saud H, Al-Mulla F, Almourfi F, Al-Muhsen SZ, Alsohime F, Al Turki S, Hasanato R, van de Beek D, Biondi A, Bettini LR, D’Angio M, Bonfanti P, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Oler AJ, Tompkins MF, Alba C, Vandernoot I, Goffard JC, Smits G, Migeotte I, Haerynck F, Soler-Palacin P, Martin-Nalda A, Colobran R, Morange PE, Keles S, Çölkesen F, Ozcelik T, Yasar KK, Senoglu S, Karabela ŞN, Gallego CR, Novelli G, Hraiech S, Tandjaoui-Lambiotte Y, Duval X, Laouénan C; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-19; Biobank; COVID Human Genetic Effort; NIAID-USUHS; TAGC COVID Immunity Group, Snow AL, Dalgard CL, Milner J, Vinh DC, Mogensen TH, Marr N, Spaan AN, Boisson B, Boisson-Dupuis S, Bustamante J, Puel A, Ciancanelli M, Meyts I, Maniatis T, Soumelis V, Amara A, Nussenzweig M, García-Sastre A, Krammer F, Pujol A, Duffy D, Lifton R, Zhang SY, Gorochov G, Béziat V, Jouanguy E, Sancho-Shimizu V, Rice CM, Abel L, Notarangelo LD, Cobat A, Su HC, Casanova JL. 2020 Sep 24. PMID: 32972995
SARS-CoV-2 vaccines in development. Krammer F. 2020 Sep 23. PMID: 32967006
Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. Shukla R, Beesetti H, Brown JA, Ahuja R, Ramasamy V, Shanmugam RK, Poddar A, Batra G, Krammer F, Lim JK, Kale S, Lal AA, Swaminathan S, Khanna N. 2020 Sep 15. PMID: 32949997
Correctly folded – but not necessarily functional – influenza virus neuraminidase is required to induce protective antibody responses in mice. McMahon M, Strohmeier S, Rajendran M, Capuano C, Ellebedy AH, Wilson PC, Krammer F. 2020 Sep 15. PMID: 32943267
SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, Zheng NY, Utset H, Stamper CT, Dugan HL, Miller WD, Huang M, Dai YN, Nelson CA, Hall PD, Jansen M, Shanmugarajah K, Donington JS, Krammer F, Fremont D, Joachimiak A, Kawaoka Y, Tesic V, Madariaga ML, Wilson PC. 2020 Sep 13. PMID: 32935099
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen FT, Amanat F, Stadlbauer D, Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E, Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. 2020 Sep 15. PMID: 32934372
SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19. Britton GJ, Chen-Liaw A, Cossarini F, Livanos AE, Spindler MP, Plitt T, Eggers J, Mogno I, Gonzalez-Reiche A, Siu S, Tankelevich M, Grinspan L, Dixon RE, Jha D, Martinez-Delgado G, Amanat F, Hoagland DA, tenOever B, Dubinsky MC, Merad M, van Bakel H, Krammer F, Bongers G, Mehandru S, Faith JJ. 2020 Sep 5. PMID: 32909002
Characterization of novel cross-reactive influenza B virus hemagglutinin head specific antibodies that lack hemagglutinin inhibition activity. Kirkpatrick E, Henry C, McMahon M, Jiang K, Strohmeier S, van Bakel H, Wilson PC, Krammer F. 2020 Sep 9. PMID: 32907980
Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, Eguia R, Amanat F, Walls AC, Wolf CR, Murphy M, Pettie D, Carter L, Qin X, King NP, Veesler D, Krammer F, Dickerson JA, Chu HY, Englund JA, Bloom JD. 2020 Sep 1. PMID: 32873791
Human germinal centres engage memory and naive B cells after influenza vaccination. Turner JS, Zhou JQ, Han J, Schmitz AJ, Rizk AA, Alsoussi WB, Lei T, Amor M, McIntire KM, Meade P, Strohmeier S, Brent RI, Richey ST, Haile A, Yang YR, Klebert MK, Suessen T, Teefey S, Presti RM, Krammer F, Kleinstein SH, Ward AB, Ellebedy AH. 2020 Aug 31. PMID: 32866963
A High Through-Put Assay For Circulating Antibodies Directed Against The S Protein Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2). Weiss S, Klingler J, Hioe C, Amanat F, Baine I, Arinsburg S, Kojic EM, Stoever J, Liu STH, Jurczyszak D, Bermudez-Gonzalez M, Simon V, Krammer F, Zolla-Pazner S. 2020 Aug 29. PMID: 32860510
Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I, Arinsburg S, Bandres JC, Siddiquey MN, Schilke RM, Woolard MD, Zhang H, Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK, Gamarnik AV, Hioe CE, Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2020 Aug 15. PMID: 32817961
Anti-SARS-CoV-2 Spike Antibodies are Stable in Convalescent Plasma when Stored at 4° Celsius for at Least 6 Weeks. Stadlbauer D, Baine I, Amanat F, Jiang K, Lally K, Krammer F, Jhang JS, Arinsburg SA. 2020 Aug 14. PMID: 32798271
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Castaño D, Amanat F, Muramatsu H, Oguin TH 3rd, Ojha A, Zhang L, Mu Z, Parks R, Manzoni TB, Roper B, Strohmeier S, Tombácz I, Arwood L, Nachbagauer R, Karikó K, Greenhouse J, Pessaint L, Porto M, Putman-Taylor T, Strasbaugh A, Campbell TA, Lin PJC, Tam YK, Sempowski GD, Farzan M, Choe H, Saunders KO, Haynes BF, Andersen H, Eisenlohr LC, Weissman D, Krammer F, Bates P, Allman D, Locci M, Pardi N. 2020 Jul 30. PMID: 32783919
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schaefer A, Dinnon KH, Innis BL, Garcia-Sastre A, Krammer F, Baric RS, Palese P. 2020 Jul 31. PMID: 32766572
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate. Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, Amanat F, Schaefer A, Dinnon K, Garcia-Sastre A, Krammer F, Baric RS, Palese P. 2020 Jul 26. PMID: 32743571
Surveillance of European Domestic Pig Populations Identifies an Emerging Reservoir of Potentially Zoonotic Swine Influenza A Viruses. Henritzi D, Petric PP, Lewis NS, Graaf A, Pessia A, Starick E, Breithaupt A, Strebelow G, Luttermann C, Parker LMK, Schröder C, Hammerschmidt B, Herrler G, Beilage EG, Stadlbauer D, Simon V, Krammer F, Wacheck S, Pesch S, Schwemmle M, Beer M, Harder TC. 2020 Jul 23. PMID: 32721380
An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses. Hong JP, Reynoso GV, Andhey PS, Swain A, Turner JS, Boon ACM, Krammer F, Ellebedy AH, Zanini F, Artyomov M, Hickman HD, Diamond MS. 2020 Jun 23. PMID: 32699843
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Gruber C, Patel R, Trachman R, Lepow L, Amanat F,Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, Simons N, Barcessat V, Del Valle D, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Rahman A, Kim-Schulze S, Charney A, Gnjatic S, Gelb B, Merad M, Bogunovic D. 2020 Jul 6. PMID: 32676612
Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection. Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini M. 2020 Jul 6. PMID: 32676603
Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Ellebedy AH, Nachbagauer R, Jackson KJL, Dai YN, Han J, Alsoussi WB, Davis CW, Stadlbauer D, Rouphael N, Chromikova V, McCausland M, Chang CY, Cortese M, Bower M, Chennareddy C, Schmitz AJ, Zarnitsyna VI, Lai L, Rajabhathor A, Kazemian C, Antia R, Mulligan MJ, Ward AB, Fremont DH, Boyd SD, Pulendran B, Krammer F, Ahmed R. 2020 Jul 13. PMID: 32661157
Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Marathe BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, Jones J, Webby RJ, Krammer F, Govorkova EA. 2020 Jul 6. PMID: 32631823
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Alsoussi WB, Turner JS, Case JB, Zhao H, Schmitz AJ, Zhou JQ, Chen RE, Lei T, Rizk AA, McIntire KM, Winkler ES, Fox JM, Kafai NM, Thackray LB, Hassan AO, Amanat F, Krammer F, Watson CT, Kleinstein SH, Fremont DH, Diamond MS, Ellebedy AH. 2020 Jun 26. PMID: 32591393
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, Liu WC, Albrecht RA, Simon V, Martinez-Sobrido L, Moran T, García-Sastre A, Krammer F. 2020 Sep. PMID: 32585083
Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses. Choi A, Ibañez LI, Strohmeier S, Krammer F, García-Sastre A, Schotsaert M. 2020 Jun 9. PMID: 32582220
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y. 2020 Jul 14. PMID: 32571934
Seroconversion in household members of COVID-19 outpatients. Cox RJ, Brokstad KA, Krammer F, Langeland N; Bergen COVID-19 Research Group. 2020 Jun 15. PMID: 32553187
A High Through-put Assay for Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory Syndrome Corona virus 2. Weiss S, Klingler J, Hioe C, Amanat F, Baine I, Kojic EM, Stoever J, Liu S, Jurczyszak D, Bermudez-Gonzalez M, Simon V, Krammer F, Zolla-Pazner S. 2020 Apr 17. PMID: 32511609
Seroprevalence of SARS-CoV-2 among children visiting a hospital during the initial Seattle outbreak. Dingens AS, Crawford KH, Adler A, Steele SL, Lacombe K, Eguia R, Amanat F, Walls AC, Wolf CR, Murphy M, Pettie D, Carter L, Qin X, King NP, Veesler D, Krammer F, Chu HY, Englund JA, Bloom JD. 2020 May 28. PMID: 32511483
Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. Chakraborty S, Edwards K, Buzzanco AS, Memoli MJ, Sherwood R, Mallajosyula V, Xie MM, Gonzalez J, Buffone C, Kathale N, Providenza S, Jagannathan P, Andrews JR, Blish CA, Krammer F, Dugan H, Wilson PC, Pham TD, Boyd SD, Zhang S, Taubenberger JK, Morales T, Schapiro JM, Parsonnet J, Wang TT. 2020 May 18. PMID: 32511463
A serological assay to detect SARS-CoV-2 seroconversion in humans. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Asthagiri Arunkumar G, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer D, Amarilis Lugo L, Milunka Kojic E, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, Garcia-Sastre A, Caplivski D, Cheng A, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. 2020 Apr 16. PMID: 32511441
Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals. Zheng A, Sun W, Xiong X, Freyn AW, Peukes J, Stromeier S, Nachbagauer R, Briggs JAG, Krammer F, Palese P. 2020 Jun 3. PMID: 32493826
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. 2020 May 20. PMID: 32473127
Introductions and Early Spread of SARS-CoV-2 in the New York City Area. Gonzalez-Reiche AS, Hernandez MM, Sullivan MJ, Ciferri B, Alshammary H, Obla A, Fabre S, Kleiner G, Polanco J, Khan Z, Alburquerque B, van de Guchte A, Dutta J, Francoeur N, Melo BS, Oussenko I, Deikus G, Soto J, Sridhar SH, Wang YC, Twyman K, Kasarskis A, Altman DR, Smith M, Sebra R, Aberg J, Krammer F, García-Sastre A, Luksza M, Patel G, Paniz-Mondolfi A, Gitman M, Sordillo EM, Simon V, van Bakel H. 2020 May 29. PMID: 32471856
Serology Assays to Manage COVID-19. Krammer F, Simon V. 2020 Jun 5. PMID: 32414781
Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. Hains DS, Schwaderer AL, Carroll AE, Starr MC, Wilson AC, Amanat F, Krammer F. 2020 May 14. PMID: 32407440
A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. 2020 May 12. PMID: 32398876
Antibody Responses to Influenza A(H1N1)pdm Infection. Wraith S, Nachbagauer R, Balmaseda A, Stadlbauer D, Ojeda S, Rajabhathor A, Lopez R, Guglia AF, Sanchez N, Amanat F, Gresh L, Kuan G, Krammer F, Gordon A. 2020 Jun 2. PMID: 32389495
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D, Krammer F, Coughlan L, Palese P, Pardi N, Nachbagauer R. 2020 Apr 19. PMID: 32359470
Zika Virus Envelope Nanoparticle Antibodies Protect Mice Without Risk of Disease Enhancement. Shukla R, Shanmugam RK, Ramasamy V, Arora U, Batra G, Acklin JA, Krammer F, Lim JK, Swaminathan S, Khanna N. 2020 Apr. PMID: 32305868
SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. 2020 Jun. PMID: 32302069
SARS-CoV-2 Vaccines: Status Report. Amanat F, Krammer F. 2020 Apr 14. PMID: 32259480
Neutralizing Monoclonal Antibodies Against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect From Virus Challenge in a Preclinical Hamster Model. Duehr J, McMahon M, Williamson B, Amanat F, Durbin A, Hawman DW, Noack D, Uhl S, Tan GS, Feldmann H, Krammer F. 2020 Mar 24. PMID: 32209676
High-complexity extracellular barcoding using a viral hemagglutinin.
Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults. Meade P, Kuan G, Strohmeier S, Maier HE, Amanat F, Balmaseda A, Ito K, Kirkpatrick E, Javier A, Gresh L, Nachbagauer R, Gordon A, Krammer F. 2020 Jan 21. PMID:31964741
Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. Chromikova V, Tan J, Aslam S, Rajabhathor A, Bermudez-Gonzalez M, Ayllon J, Simon V, García-Sastre A, Salaun B, Nachbagauer R, Krammer F. 2020 Jan 17. PMID:31959425
2019 Publications
Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A Viruses. Muñoz-Moreno R, Martínez-Romero C, Blanco-Melo D, Forst CV, Nachbagauer R, Benitez AA, Mena I, Aslam S, Balasubramaniam V, Lee I, Panis M, Ayllón J, Sachs D, Park MS, Krammer F, tenOever BR, García-Sastre A. 2019 Dec 17. PMID:31851929
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. Nachbagauer R, Salaun B, Stadlbauer D, Behzadi MA, Friel D, Rajabhathor A, Choi A, Albrecht RA, Debois M, García-Sastre A, Rouxel RN, Sun W, Palese P, Mallett CP, Innis BL, Krammer F, Claeys C. 2019 Dec 6. PMID:31839997
Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. Krammer F, Weir JP, Engelhardt O, Katz JM, Cox RJ. 2019 Dec 13. PMID:31837382
Monoclonal antibodies with neutralizing activity and Fc-effector functions against the Machupo virus glycoprotein. Amanat F, Duehr J, Huang C, Paessler S, Tan G, Krammer F. 2019 Dec 4. PMID:31801871
Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Stadlbauer D, Zhu X, McMahon M, Turner JS, Wohlbold TJ, Schmitz AJ, Strohmeier S, Yu W, Nachbagauer R, Mudd PA, Wilson IA, Ellebedy AH, Krammer F. 2019 Oct 25. PMID:31649200
A full publication list can be found here:
https://www.ncbi.nlm.nih.gov/pubmed/?term=Krammer+F%5BAuthor%5D